The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
ATR/CHK1 inhibitors and cancer therapy
Open accessAbstract
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase (ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of cells with damaged or incompletely replicated DNA into mitosis when the cells are challenged by DNA damaging agents, such as radiation therapy (RT) or chemotherapeutic drugs, that are the major modalities to treat cancer. This regulation is particularly evident in cells with a defective G1 checkpoint, a common feature of cancer cells, due to p53 mutations. In addition, ATR and/or CHK1 suppress replication stress (RS) by inhibiting excess origin firing, particularly in cells with activated oncogenes. Those functions of ATR/CHK1 make them ideal therapeutic targets. ATR/CHK1 inhibitors have been developed and are currently used either as single agents or paired with radiotherapy or a variety of genotoxic chemotherapies in preclinical and clinical studies. Here, we review the status of the development of ATR and CHK1 inhibitors. We also discuss the potential mechanisms by which ATR and CHK1 inhibition induces cell killing in the presence or absence of exogenous DNA damaging agents, such as RT and chemotherapeutic agents. Lastly, we discuss synthetic lethality interactions between the inhibition of ATR/CHK1 and defects in other DNA damage response (DDR) pathways/genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Šalovská, B., Fabrik, I., Ďurišová, K., Link, M., Vávrová, J., Řezáčová, M., & Tichý, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150712007 · Cited by 27
Fuse, E., Hashimoto, A., Sato, N., Tanii, H., Kuwabara, T., Kobayashi, S., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007512832006 · Cited by 25
ATR Suppresses Endogenous DNA Damage and Allows Completion of Homologous Recombination Repair
Brown, A., Sager, B. W., Gorthi, A., Tonapi, S. S., Brown, E. J., & Bishop, A. J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091222 · Cited by 21
Rini, B. I., WEINBERG, V. K., Shaw, V., Scott, J. H., Bok, R., Park, J. W., & Small, E. J. (2004) · Cancer · doi:10.1002/cncr.20313 · Cited by 19
Hattori, H., Skoulidis, F., Russell, P. A., & Venkitaraman, A. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0781 · Cited by 19
Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells
Mordasini, V., Ueda, S., Aslandogmus, R., Berger, C., Gysin, C., Hühn, D., Sartori, A. A., Bernasconi, M., & Nadal, D. (2016) · Oncotarget · doi:10.18632/oncotarget.14120 · Cited by 19
Mitchell, C., Hamed, H. A., Cruickshanks, N. A., Tang, Y., Bareford, M. D., Hubbard, N., Tye, G. W., Yacoub, A., Dai, Y., Grant, S., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.3.16218 · Cited by 17
Differential Effect of Schisandrin B Stereoisomers on ATR-Mediated DNA Damage Checkpoint Signaling
Tatewaki, N., Nishida, H., Yoshida, M., Ando, H., Kondo, S., Sakamaki, T., & Konishi, T. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13048fp · Cited by 15
Wickremsinhe, E. R., Hynes, S. M., Palmieri, M. D., Mitchell, M. I., Abraham, T. L., Rehmel, J., Chana, E., Jost, L. M., & Cassidy, K. C. (2014) · Xenobiotica · doi:10.3109/00498254.2014.900589 · Cited by 11
Pollard, J. R., Reaper, P. M., Peek, A., Hughes, S. W., Djeha, H., Cummings, S. R., Larbi, K. Y., Penney, M. S., Sullivan, J., Takemoto, D., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3711 · Cited by 4
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Pan, L., Feng, F., Wu, J., Fan, S., Han, J., Wang, S., Yang, L., Liu, W., Wang, C., & Xu, K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106270 · Cited by 383
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Ghelli Luserna di Rorà, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00959-2 · Cited by 314
Metadata
- Authors
- Qiu, Z., Oleinick, N. L., & Zhang, J.
- Venue
- Radiotherapy and Oncology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 126
- Issue
- 3
- Pages
- 450-464
- ISSN
- 0167-8140 (ISSN-L)
- OpenAlex
- W2766300480
- Cited by
- 370
- References
- 210
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.